Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2016

Open Access 01-05-2016 | Review

The role of ANGPTL3 in controlling lipoprotein metabolism

Authors: Anna Tikka, Matti Jauhiainen

Published in: Endocrine | Issue 2/2016

Login to get access

Abstract

Angiopoietin-like protein 3 (ANGPTL3) is a secretory protein regulating plasma lipid levels via affecting lipoprotein lipase- and endothelial lipase-mediated hydrolysis of triglycerides and phospholipids. ANGPTL3-deficiency due to loss-of-function mutations in the ANGPTL3 gene causes familial combined hypobetalipoproteinemia (FHBL2, OMIM # 605019), a phenotype characterized by low concentration of all major lipoprotein classes in circulation. ANGPTL3 is therefore a potential therapeutic target to treat combined hyperlipidemia, a major risk factor for atherosclerotic coronary heart disease. This review focuses on the mechanisms behind ANGPTL3-deficiency induced FHBL2.
Literature
1.
T.G. Redgrave, Chylomicrons, in Lipoproteins in Health and Disease, ed. by D.J. Betteridge, D.R. Illingworth, J. Shepherd (Arnold, London, 1999), pp. 31–54
2.
H.N. Ginsberg, J.L. Dixon, I.J. Goldberg, Illingworth, J. Shepherd, VLDL/LDL cascade system: assembly, secretion and intravascular metabolism of apoprotein B-containing lipoproteins, in Lipoproteins in Health and Disease, ed. by D.J. Betteridge (Arnold, London, 1999), pp. 55–70
3.
C.J. Packard, J. Shepher, Physiology of the lipoprotein transport system: an overview of lipoprotein metabolism, in Lipoproteins in Health and Disease, ed. by D.J. Betteridge, D.R. Illingworth, J. Shepherd (Arnold, London, 1999), pp. 17–30
4.
I.J. Goldberg, R.H. Eckel, N.A. Abumrad, Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways. J Lipid Res. 50, S86–S90 (2009)CrossRefPubMedPubMedCentral
5.
A.R. Tall, L. Yvan-Charvet, N. Terasaka, T. Pagler, N. Wang, HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 7(5), 365–375 (2008)CrossRefPubMed
6.
C. Willer et al., Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 40(2), 161–169 (2008)CrossRefPubMed
7.
S. Kathiresan, O. Melander, C. Guiducci, A. Surti, NP. Burtt, MJ. Rieder, GM. Cooper, C. Roos, BF. Voight, AS. Havulinna, B. Wahlstrand, T. Hedner, D. Corella, ES. Tai, JM. Ordovas, G. Berglund, E. Vartiainen, P. Jousilahti, B. Hedblad, MR. Taskinen, C. Newton-Cheh, V. Salomaa, L. Peltonen, L. Groop, DM. Altshuler, M. Orho-Melander, Sixnew loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 40(2),189–97 (2008). Erratum in: Nat. Genet. 40(11):1384 (2008)
8.
N. Woolf, Pathology of atherosclerosis, in Lipoproteins in Health and Disease, ed. by D.J. Betteridge, D.R. Illingworth, J. Shepherd (Arnold, London, 1999), pp. 533–540
9.
B.G. Nordestgaard, M. Benn, P. Schnohr, A. Tybjaerg-Hansen, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298(3), 299–308 (2007)CrossRefPubMed
10.
H.L. Staniak, W. Salgado Filho, M.H. Miname, I.M. Benseñor, P.A. Lotufo, R. Sharovsky, C.E. Rochitte, R.D. Bittencourt, R.D. Santos, Association between postprandialtriglycerides and coronary artery disease detected by coronary computed tomography angiography. Atherosclerosis 233(2), 381–386 (2014)CrossRefPubMed
11.
R.C. Oh, J.B. Lanier, Management of hypertriglyceridemia. Am Fam. Physician. 75(9), 1365–1371 (2007)PubMed
12.
T. Hato, M. Tabata, Y. Oike, The role of angiopoietin-like proteins in angiogenesis and metabolism. Trends Cardiovasc. Med. 18, 6–14 (2008)CrossRefPubMed
13.
D. Conklin, D. Gilbertson, D.W. Taft, M.F. Maurer, T.E. Whitmore, D.L. Smith, K.M. Walker, L.H. Chen, S. Wattler, M. Nehls, K.B. Lewis, Identification of a mammalian angiopoietin-related protein expressed specifically in liver. Genomics 62(3), 477–482 (1999)CrossRefPubMed
14.
M. Ono, T. Shimizugawa, M. Shimamura, K. Yoshida, C. Noji-Sakikawa, Y. Ando, R. Koishi, H. Furukawa, Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo. J Biol. Chem. 278(43), 41804–41809 (2003)CrossRefPubMed
15.
L. Shan, X.C. Yu, Z. Liu, Y. Hu, L.T. Sturgis, M.L. Miranda, Q. Liu, The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. J Biol. Chem. 284(3), 1419–1424 (2009)CrossRefPubMedPubMedCentral
16.
G. Camenisch, M.T. Pisabarro, D. Sherman, J. Kowalski, M. Nagel, P. Hass, M.H. Xie, A. Gurney, S. Bodary, X.H. Liang, K. Clark, M. Beresini, N. Ferrara, H.P. Gerber, ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo. J Biol. Chem. 277(19), 17281–17290 (2002)CrossRefPubMed
17.
W. Jin, X. Wang, J.S. Millar, T. Quertermous, G.H. Rothblat, J.M. Glick, D.J. Rader, Hepatic proprotein convertases modulate HDL metabolism. Cell Metab. 6(2), 129–136 (2007)CrossRefPubMedPubMedCentral
18.
F. Quagliarini, Y. Wang, J. Kozlitina, N.V. Grishin, R. Hyde, E. Boerwinkle, D.M. Valenzuela, A.J. Murphy, J.C. Cohen, H.H. Hobbs, Atypical angiopoietin-like protein that regulates ANGPTL3. Proc. Natl. Acad. Sci. USA 109(48), 19751–19756 (2012)CrossRefPubMedPubMedCentral
19.
Z. Fu, F. Yao, A.B. Abou-Samra, R. Zhang, Lipasin, thermoregulated in brown fat, is a novel but atypical member of the angiopoietin-like protein family. Biochem. Biophys. Res. Commun. 430(3), 1126–1131 (2013)CrossRefPubMed
20.
R. Zhang, A.B. Abou-Samra, A dual role of lipasin (betatrophin) in lipid metabolism and glucose homeostasis: consensus and controversy. Cardiovasc. Diabetol. 13, 133 (2014)CrossRefPubMedPubMedCentral
21.
R. Koishi, Y. Ando, M. Ono, M. Shimamura, H. Yasumo, T. Fujiwara, H. Horikoshi, H. Furukawa, Angptl3 regulates lipid metabolism in mice. Nat. Genet. 30(2), 151–157 (2002)CrossRefPubMed
22.
T. Shimizugawa, M. Ono, M. Shimamura, K. Yoshida, Y. Ando, R. Koishi, K. Ueda, T. Inaba, H. Minekura, T. Kohama, H. Furukawa, ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J. Biol. Chem. 277(37), 33742–33748 (2002)CrossRefPubMed
23.
Y. Ando, T. Shimizugawa, S. Takeshita, M. Ono, M. Shimamura, R. Koishi, H. Furukawa, A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice. J. Lipid Res. 44(6), 1216–1223 (2003)CrossRefPubMed
24.
25.
S. Romeo, W. Yin, J. Kozlitina, L.A. Pennacchio, E. Boerwinkle, H.H. Hobbs, J.C. Cohen, Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin. Invest. 119(1), 70–79 (2009)PubMedPubMedCentral
26.
I. Minicocci, A. Montali, M.R. Robciuc, F. Quagliarini, V. Censi, G. Labbadia, C. Gabiati, G. Pigna, M.L. Sepe, F. Pannozzo, D. Lütjohann, S. Fazio, M. Jauhiainen, C. Ehnholm, M. Arca, Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization. J. Clin. Endocrinol. Metab. 97(7), E1266–E1275 (2012)CrossRefPubMed
27.
28.
M. Arca, I. Minicocci, M. Maranghi, The angiopoietin-like protein 3: a hepatokine with expanding role in metabolism. Curr. Opin. Lipidol. 24(4), 313–320 (2013)CrossRefPubMed
29.
J.M. Martín-Campos, R. Roig, C. Mayoral, S. Martinez, G. Marti, J.A. Arroyo, J. Julve, F. Blano-Vaca, Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation. Clin. Chim. Acta. 413, 552–555 (2012)CrossRefPubMed
30.
L. Pisciotta et al., Characterization of three kindred with familial combined hypolipidemia due to loss of function mutations of ANGPTL3. Cardiovasc. Genet. 5, 42–50 (2012)CrossRef
31.
D. Noto, A.B. Cefalù, V. Valenti, F. Fayer, E. Pinotti, M. Ditta, R. Spina, G. Vigna, P. Yue, S. Kathiresan, P. Tarugi, M.R. Averna, Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipidemia. Arterioscler. Thromb. Vasc. Biol. 32(3), 805–809 (2012)CrossRefPubMed
32.
K. Hirata, H.L. Dichek, J.A. Cioffi, S.Y. Choi, N.J. Leeper, L. Quintana, G.S. Kronmal, A.D. Cooper, T. Quertermous, Cloning of a unique lipase from endothelial cells extends the lipase gene family. J. Biol. Chem. 274(20), 14170–14175 (1999)CrossRefPubMed
33.
M.G. McCoy, G.S. Sun, D. Marchadier, C. Maugeais, J.M. Glick, D.J. Rader, Characterization of the lipolytic activity of endothelial lipase. J. Lipid Res. 43, 921–929 (2002)PubMed
34.
M.R. Robciuc, M. Maranghi, A. Lahikainen, D. Rader, A. Bensadoun, K. Öörni, J. Metso, I. Minicocci, E. Ciociola, F. Ceci, A. Montali, M. Arca, C. Ehnholm, M. Jauhiainen, Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Arterioscler. Thromb. VascBiol. 33(7), 1706–1713 (2013)CrossRef
35.
J. Liu, H. Afroza, D.J. Rader, W. Jin, Angiopoietin-like protein 3 inhibits lipoprotein lipase activity through enhancing its cleavage by proprotein convertases. J. Biol. Chem. 285(36), 27561–27570 (2010)CrossRefPubMedPubMedCentral
36.
M. Shimamura, M. Matsuda, H. Yasumo, M. Okazaki, K. Fujimoto, K. Kono, T. Shimizugawa, Y. Ando, R. Koishi, T. Kohama, N. Sakai, K. Kotani, R. Komuro, T. Ishida, K. Hirata, S. Yamashita, H. Furukawa, I. Shimomura, Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler. Thromb. Vasc. Biol. 27(2), 366–372 (2007)CrossRefPubMed
37.
Y. Wang, M.C. McNutt, S. Banfi, M.G. Levin, W.L. Holland, V. Gusarova, J. Gromada, J.C. Cohen, H.H. Hobbs, Hepatic ANGPTL3 regulates adipose tissue energy homeostasis. Proc. Natl. Acad. Sci. USA 112(37), 11630–11635 (2015)CrossRefPubMedPubMedCentral
38.
Y. Wang, V. Gusarova, S. Banfi, J. Gromada, J.C. Cohen, H.H. Hobbs, Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. J. Lipid Res. 56(7), 1296–1307 (2015)CrossRefPubMed
39.
M. Jaye, K.J. Lynch, J. Krawiec, D. Marchadier, C. Maugeais, K. Doan, V. South, D. Amin, M. Perrone, D.J. Rader, A novel endothelial-derived lipase that modulates HDL metabolism. Nat. Genet. 21(4), 424–428 (1999)CrossRefPubMed
40.
J.W. Gofman, W. Young, R. Tandy, Ischemic heart disease, atherosclerosis, and longevity. Circulation 34(4), 679–697 (1966)CrossRefPubMed
41.
42.
M.C. Moore, K.C. Coate, J.J. Winnick, Z. An, A.D. Cherrington, Regulation of hepatic glucose uptake and storage in vivo. Adv. Nutr. 3(3), 286–294 (2012)CrossRefPubMedPubMedCentral
43.
M. Adiels, J. Westerbacka, A. Soro-Paavonen, A.M. Häkkinen, S. Vehkavaara, M.J. Caslake, C. Packard, S.O. Olofsson, H. Yki-Järvinen, M.R. Taskinen, J. Borén, Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 50(11), 2356–2365 (2007)CrossRefPubMed
44.
A. Tikka, J. Soronen, P.P. Laurila, J. Metso, C. Ehnholm, M. Jauhiainen, Silencing of ANGPTL 3 (angiopoietin-like protein 3) in human hepatocytes results in decreased expression of gluconeogenic genes and reduced triacylglycerol-rich VLDL secretion upon insulin stimulation. Biosci. Rep. 34(6), e00160 (2014)CrossRefPubMedPubMedCentral
45.
M. Baranowski, Biological role of liver X receptors. J. Physiol. Pharmacol. 59(Suppl 7), 31–55 (2008)PubMed
46.
S.D. Lee, P. Tontonoz, Liver X receptors at the intersection of lipid metabolism and atherogenesis. Atherosclerosis 242(1), 29–36 (2015)CrossRefPubMed
47.
B.A. Laffitte, L.C. Chao, J. Li, R. Walczak, S. Hummasti, S.B. Josephm, A. Castrillo, D.C. Wilpitz, D.J. Mangelsdorf, J.L. Collins, E. Saez, P. Tontonoz, Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc. Natl. Acad. Sci. USA 100(9), 5419–5424 (2003)CrossRefPubMedPubMedCentral
48.
R. Kaplan, T. Zhang, M. Hernandez, R.X. Gan, S.D. Wright, M.G. Waters, T.Q. Cai, Regulation of the angiopoietin-like protein 3 gene by LXR. J. Lipid Res. 44(1), 136–143 (2003)CrossRefPubMed
49.
T. Inaba, M. Matsuda, M. Shimamura, N. Takei, N. Terasaka, Y. Ando, H. Yasumo, R. Koishi, M. Makishima, I. Shimomura, Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor. J. Biol. Chem. 278(24), 21344–21351 (2003)CrossRefPubMed
50.
S.M. Choi, D.F. Tucker, D.N. Gross, R.M. Easton, L.M. DiPilato, A.S. Dean, B.R. Monks, M.J. Birnbaum, Insulin regulates adipocyte lipolysis via an Akt-independent signaling pathway. Mol. Cell Biol. 30(21), 5009–5020 (2010)CrossRefPubMedPubMedCentral
51.
M. Shimamura, M. Matsuda, S. Kobayashi, Y. Ando, M. Ono, R. Koishi, H. Furukawa, M. Makishima, I. Shimomura, Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes. Biochem. Biophys. Res. Commun. 301(2), 604–609 (2003)CrossRefPubMed
52.
53.
J.I. Pulai, R.J. Neuman, A.W. Groenewegen, J. Wu, G. Schonfeld, Genetic heterogeneity in familial hypobetalipoproteinemia: linkage and non-linkage to the apoB gene in Caucasian families. Am. J. Med. Genet. 76, 79–86 (1998)CrossRefPubMed
54.
V. Gusarova, C.A. Alexa, Y. Wang, A. Rafique, J.H. Kim, D. Buckler, I.J. Mintah, L.M. Shihanian, J.C. Cohen, H.H. Hobbs, Y. Xin, D.M. Valenzuela, A.J. Murphy, G.D. Yancopoulos, J. Gromada, ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J. Lipid Res. 56(7), 1308–1317 (2015)CrossRefPubMed
Metadata
Title
The role of ANGPTL3 in controlling lipoprotein metabolism
Authors
Anna Tikka
Matti Jauhiainen
Publication date
01-05-2016
Publisher
Springer US
Published in
Endocrine / Issue 2/2016
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-015-0838-9

Other articles of this Issue 2/2016

Endocrine 2/2016 Go to the issue

Original Article

Postprandial hyperglycemia was ameliorated by taking metformin 30 min before a meal than taking metformin with a meal; a randomized, open-label, crossover pilot study

Original Article

Long-term exposure to electromagnetic radiation from mobile phones and Wi-Fi devices decreases plasma prolactin, progesterone, and estrogen levels but increases uterine oxidative stress in pregnant rats and their offspring

Original Article

Reducing glucose variability with continuous subcutaneous insulin infusion increases endothelial progenitor cells in type 1 diabetes: an observational study

Original Article

Calcitriol attenuates cardiac remodeling and dysfunction in a murine model of polycystic ovary syndrome

Editorial

Vitamin D-binding protein: one more piece in the puzzle of acromegalic osteopathy?

Original Article

Usefulness of NRAS codon 61 mutation analysis and core needle biopsy for the diagnosis of thyroid nodules previously diagnosed as atypia of undetermined significance
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits